Curated News
By: NewsRamp Editorial Staff
August 14, 2025
Soligenix Reports Q2 2025 Results and Advances Rare Disease Treatments
TLDR
- Soligenix's advancements in rare disease treatments, including Phase 2a results for SGX302 in psoriasis and Phase 3 trial of HyBryte(TM) for CTCL, offer investors potential growth opportunities.
- Soligenix reported a Q2 2025 net loss of $2.7 million, with R&D expenses rising to $1.7 million due to increased trial and manufacturing costs, while maintaining $5.1 million in cash.
- Soligenix's development of treatments for rare diseases like CTCL and Behçet’s Disease represents a significant step forward in improving patient care and quality of life.
- Soligenix transfers synthetic hypericin manufacturing to the U.S., marking a strategic move in its partnership with Sterling Pharma Solutions for rare disease treatments.
Impact - Why it Matters
This news is significant for patients with rare diseases and investors in the biopharmaceutical sector. Soligenix's progress in developing treatments for conditions like psoriasis, CTCL, and Behçet’s Disease represents potential new options for patients with limited treatment choices. The company's financial health and pipeline advancements also offer insights into the viability of investing in biotech firms focused on rare diseases, highlighting the intersection of healthcare innovation and investment opportunities.
Summary
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, has announced its Q2 2025 results and recent milestones, highlighting progress in its pipeline of treatments for rare diseases. Key developments include the anticipation of top-line Phase 2a results for SGX302 in mild-to-moderate psoriasis by year-end and updates from its HyBryte(TM) study for early-stage cutaneous T-cell lymphoma (CTCL). The company has also completed a Phase 2a proof-of-concept study for SGX945 in Behçet’s Disease, achieving its primary objective. Despite a widened net loss to $2.7 million, Soligenix's cash position, bolstered by recent funding, supports operations into Q1 2026. The company's efforts in both its Specialized BioTherapeutics and Public Health Solutions business segments underscore its commitment to addressing unmet medical needs through innovative treatments and vaccines.
For more details, visit the full press release at https://ibn.fm/SsFsy.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix Reports Q2 2025 Results and Advances Rare Disease Treatments
